Info
Significant Ownership

Significant Ownership of Foresite Capital Fund IV, L.P.

Signature - Title: /s/ James Tananbaum - James Tananbaum, Managing Member of the General Partner
Location: San Francisco, CA
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by Foresite Capital Fund IV, L.P..

Notify me when Foresite Capital Fund IV, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Foresite Capital Fund IV, L.P.

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
LYEL	Lyell Immunopharma, Inc.	Common Stock, par value $0.0001	9.2%	$12,766,089	+$3,611,010	27,161,892	+39%	James B. Tananbaum	31 Mar 2025
LYEL	Lyell Immunopharma, Inc.	Common Stock, par value $0.0001	7.6%	$23,622,818		1,454,616		James B. Tananbaum	30 Sep 2025
MAZE	Maze Therapeutics, Inc.	Common Stock, par value $0.001	1.4%	$15,790,022	-$47,922,789	608,948	-75%	James Tananbaum	30 Sep 2025

Schedules 13D/G Reported by Foresite Capital Fund IV, L.P.:

Sym	Target	Class	Ownership	Change	Current Shares	Change	Value	Reporting name	Form	Report Period	Filing Date

* An asterisk sign (*) next to the price indicates that the price is likely invalid.